PharmaSens和 SiBionics合作开发可穿戴胰岛素贴片泵-动脉网

PharmaSens and SiBionics to develop wearable insulin patch pump

Medical Device Network 等信源发布 2025-06-20 13:17



可切换为仅中文







Through the device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin. Credit: valiantsin suprunovich / Shutterstock.

通过该设备，相关方预计能够简化使用胰岛素的糖尿病患者的管理。 crédito: valiantsin suprunovich / Shutterstock。

Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump.

瑞士公司PharmaSens和SiBionics已就niia signature达成开发合作伙伴关系，这是一款集胰岛素输送与连续血糖监测（CGM）于一体的紧凑型泵式可穿戴设备。

Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load.

通过该设备，相关人员预计将简化使用胰岛素的糖尿病患者的管理，旨在减轻日常治疗负担。

Go deeper with GlobalData

深入探索GlobalData

Reports

报告

Insulin Pumps and Continuous Glucose Monitors Market Size (Value, V...

胰岛素泵和连续血糖监测仪市场规模（价值，V...

Reports

报告

Asia-Pacific Insulin Delivery Market Outlook to 2025

亚太地区胰岛素输送市场展望至2025年

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

The wearable will leverage PharmaSens’ patented platform technologies along with the biosensor capabilities of SiBionics.

该可穿戴设备将利用PharmaSens的专利平台技术以及SiBionics的生物传感器功能。

Both companies will offer their engineering and development know-how to bring this patch pump to the market.

两家公司都将提供其工程和开发专业知识，以将这种贴片泵推向市场。

PharmaSens CEO Marcel Both said: “This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system.

PharmaSens 首席执行官马塞尔·博斯 (Marcel Both) 表示：“这一合作伙伴关系标志着我们实现全集成、谨慎且直观的胰岛素治疗系统愿景的重要里程碑。”

“SiBionics’ proven expertise in sensor technology is a perfect complement to our platform.”

“SiBionics在传感器技术方面经过验证的专业知识是对我们平台的完美补充。”

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预测？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由GlobalData提供

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

PharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs.

PharmaSens当前正在开发一个包含niia signature在内的三款胰岛素贴片泵的产品组合，旨在满足广泛的用户需求。

The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity.

该系列以 niia essential 开头，这是一款基础-餐时胰岛素泵，通过减少复杂性来优先考虑使用的便捷性。

The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM.

niia advanced 提供了更多的选项，并且可以通过智能手机进行控制，还允许连接到外部的 CGM。

PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste.

PharmaSens 强调，其设备由一个可重复使用的部分组成，包括泵和 CGM 电子元件，使用寿命为两年，以及一个一次性部分，其中包括一个 3 毫升的胰岛素储液器，以延长佩戴时间并减少胰岛素浪费。

The company is focused on simplifying diabetes management and expanding access to insulin pump therapy.

该公司专注于简化糖尿病管理并扩大胰岛素泵治疗的可及性。

Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US.

成立于2015年的CGM技术提供商硅基仿生为此次合作带来了其在医疗器械研发领域的核心专长，并在中国和美国设有办事处。

Last year, PharmaSens submitted an

去年，PharmaSens 提交了

application to the US Food and Drug Administration (FDA)

向美国食品药品监督管理局 (FDA) 的申请

for approval of its niia essential insulin patch pump system.

为了获得其niia胰岛素贴片泵系统的关键批准。

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

利用我们领先的行业洞察，为您的业务提供优势。

Medical Device Network Excellence Awards - Have you nominated?

医疗器械网络卓越奖——你提名了吗？